Literature DB >> 714108

Estrogen receptors and responses to chemotherapy and hormonal therapy in advanced breast cancer.

D T Kiang, D H Frenning, A I Goldman, V F Ascensao, B J Kennedy.   

Abstract

To determine the correlation between the estrogen-receptor status and responses to chemotherapy or hormonal therapy, we retrospectively analyzed the clinical data of 143 patients with advanced breast cancer. Receptor contents were determined by a sucrose-gradient method and designated arbitrarily as "rich" or "poor". The response rate to chemotherapy was significantly higher in receptor-rich tumors (86 per cent) than in receptor-poor tumors (36 per cent) (P less than 0.001). Patients with receptor-rich tumors also responded favorably to hormonal therapy. However, there was no correlation between the responses to hormonal therapy and to chemotherapy when they were used sequentially, a phenomenon that may be attributed to the changes in tumor receptor content during the clinical course. These data suggest that separate factors associated with the response to chemotherapy may coexist with estrogen receptors in breast cancer.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 714108     DOI: 10.1056/NEJM197812142992403

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  39 in total

1.  Comparison between a biochemical and a histochemical method for the detection of oestrogen receptor in breast carcinoma.

Authors:  R T McMahon; C E Connolly
Journal:  Ir J Med Sci       Date:  1985-05       Impact factor: 1.568

2.  Oestrogen receptor values and histologic type and grade in breast carcinoma--a three year review.

Authors:  B M Loftus; C E Connolly
Journal:  Ir J Med Sci       Date:  1988-02       Impact factor: 1.568

3.  Significance of the Tritiated Thymidine Labeling Index in breast cancers.

Authors:  K Araki; M Kimura; K Sakamoto; R Nishimura; M Akagi
Journal:  Jpn J Surg       Date:  1985-03

4.  Estradiol and progesterone receptors in breast cancer: prognostic value after relapse.

Authors:  J Bonneterre; D Horner; J P Peyrat; B Vandewalle; L Cambier; A Demaille
Journal:  Breast Cancer Res Treat       Date:  1985       Impact factor: 4.872

5.  The potential biomarkers in predicting pathologic response of breast cancer to three different chemotherapy regimens: a case control study.

Authors:  Linbo Wang; Zhinong Jiang; Meihua Sui; Jianguo Shen; Chaoyang Xu; Weimin Fan
Journal:  BMC Cancer       Date:  2009-07-11       Impact factor: 4.430

6.  A phase II trial of tamoxifen, premarin, methotrexate and 5-fluorouracil in metastatic breast cancer.

Authors:  J C Allegra; T M Woodcock; S P Richman; K I Bland; J L Wittliff
Journal:  Breast Cancer Res Treat       Date:  1982       Impact factor: 4.872

7.  The activity of phosphohexose isomerase in primary breast carcinomas and response to chemotherapy in patients with metastatic disease.

Authors:  I Mitchell; N Deshpande; R Millis; R D Rubens
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

8.  The influence of estradiol and adriamycin on the RNA biosynthesis in breast cancer.

Authors:  P Schlag; J Veser; G Geier; D Breitig
Journal:  J Cancer Res Clin Oncol       Date:  1980       Impact factor: 4.553

9.  Impact of grade, hormone receptor, and HER-2 status in women with breast cancer on response to specific chemotherapeutic agents by in vitro adenosine triphosphate-based chemotherapy response assay.

Authors:  Ja Seung Koo; Woohee Jung; Eunah Shin; Hy-de Lee; Joon Jeong; Kun-Hong Kim; Hyeongjae Jeong; Soon Won Hong
Journal:  J Korean Med Sci       Date:  2009-11-09       Impact factor: 2.153

10.  Retrospective analysis of 119 Chinese noninflammatory locally advanced breast cancer cases treated with intravenous combination of vinorelbine and epirubicin as a neoadjuvant chemotherapy: a median follow-up of 63.4 months.

Authors:  Ou Huang; Canming Chen; Jiayi Wu; Shujie Chen; Xiaosong Chen; Guangyu Liu; Zhen Hu; Jingsong Lu; Jiong Wu; Zhimin Shao; Zhenzhou Shen; Kunwei Shen
Journal:  BMC Cancer       Date:  2009-10-21       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.